Recent Updates
Recently added Catalysts
CRVS Negative Sentiment Score: 20/100

Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell

Key Takeaway: Corvus Pharmaceuticals has announced the passing of Edith P. Mitchell, M.D., a respected member of its Board of Directors. Dr. Mitchell, who served on the board since September 2020, had a notable career in healthcare and was recognized for her contributions to cancer care and health equity. The company expressed deep condolences to her family and colleagues, noting her impactful legacy in oncology and healthcare. Dr. Mitchell was also a pioneer as the first female Brigadier General in the U.S. Air Force.

Market Sentiment Analysis

CONCERNS & RISKS

  • The passing of Board Member Edith P. Mitchell is a significant loss for Corvus Pharmaceuticals.
  • Her absence will be felt across the company and the cancer care community.

Full Press Release Details

BURLINGAME, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, is deeply saddened to announce the passing of Edith P. Mitchell, M.D., a valued member of the Board of Directors. The Company extends its condolences to her family, colleagues and community.
“Edith had a distinguished career in healthcare, spanning patient care, education, clinical research and improving health equity,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “She was a valued member of our Board and will be remembered for her keen insights, deep understanding of oncology and exemplary character and integrity.”
Dr. Mitchell served on the Corvus Board of Directors since September 2020 and had a trailblazing career in cancer care, research and the delivery of healthcare. She served in several positions at Thomas Jefferson University, including as a clinical professor, Department of Medicine and Medical Oncology at Sidney Kimmel Medical College and enterprise vice president for cancer disparities at Sidney Kimmel Cancer Center. She also held prominent roles with medical societies and cancer organizations, and was a retired United States Air Force Brigadier General where she was the first female physician ever to achieve this rank. Dr. Mitchell also served as President of the National Medical Association in 2015.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Corvus plans to initiate a Phase 3 registrational clinical trial for soquelitinib in patients with relapsed peripheral T cell lymphoma. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.
Chief Financial Officer
Corvus Pharmaceuticals, Inc.

Frequently Asked Questions

Who was Dr. Edith P. Mitchell?

Dr. Edith P. Mitchell was a board member of Corvus Pharmaceuticals and a pioneer in cancer care.

What roles did Dr. Mitchell hold?

She was a clinical professor at Thomas Jefferson University and a Brigadier General in the Air Force.

When did Dr. Mitchell join Corvus Pharmaceuticals?

Dr. Mitchell joined the Corvus Board of Directors in September 2020.

What is Corvus Pharmaceuticals known for?

Corvus Pharmaceuticals specializes in developing ITK inhibition for cancer and immune diseases.

What is Corvus's lead product candidate?

Corvus's lead candidate is soquelitinib, aimed at treating relapsed peripheral T cell lymphoma.

Last updated: Jan 23, 2024